Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,470.00
(
-1.06%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,686.36
(
0.24%
)
News Focus
News Focus
Post# of 257265
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 51959

Thursday, 09/06/2007 4:32:45 PM

Thursday, September 06, 2007 4:32:45 PM

Post# of 257265
> MODG – FSH-CTP is in phase 3 trials now…i have my doubts it will be a success based on what i have seen/heard to date. that alone would taint any future CTP offerings in the pipeline<

MODG admits that its most consequential news flow will be the outcome of the Organon (SGP) FSH-CTP trial. It’s uncomfortable to have an unrelated party controlling your company’s valuation, but MODG knew this would happen when they licensed the residual CTP IP from WUStL.

Why are you pessimistic about this particular trial?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today